- Home
- HIFS vs MYGN Comparison
HIFS vs MYGN Comparison
Compare HIFS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIFS
- MYGN
- Stock Information
- Founded
- HIFS 1834
- MYGN 1991
- Country
- HIFS United States
- MYGN United States
- Employees
- HIFS N/A
- MYGN N/A
- Industry
- HIFS Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HIFS Finance
- MYGN Health Care
- Exchange
- HIFS Nasdaq
- MYGN Nasdaq
- Market Cap
- HIFS 595.7M
- MYGN 625.5M
- IPO Year
- HIFS N/A
- MYGN 1995
- Fundamental
- Price
- HIFS $293.29
- MYGN $7.89
- Analyst Decision
- HIFS
- MYGN Hold
- Analyst Count
- HIFS 0
- MYGN 13
- Target Price
- HIFS N/A
- MYGN $12.58
- AVG Volume (30 Days)
- HIFS 55.5K
- MYGN 1.2M
- Earning Date
- HIFS 10-10-2025
- MYGN 11-03-2025
- Dividend Yield
- HIFS 0.92%
- MYGN N/A
- EPS Growth
- HIFS 94.74
- MYGN N/A
- EPS
- HIFS 20.54
- MYGN N/A
- Revenue
- HIFS $90,528,000.00
- MYGN $825,300,000.00
- Revenue This Year
- HIFS N/A
- MYGN $0.06
- Revenue Next Year
- HIFS N/A
- MYGN $5.68
- P/E Ratio
- HIFS $13.34
- MYGN N/A
- Revenue Growth
- HIFS 54.99
- MYGN 0.21
- 52 Week Low
- HIFS $209.71
- MYGN $3.76
- 52 Week High
- HIFS $320.00
- MYGN $16.83
- Technical
- Relative Strength Index (RSI)
- HIFS 58.05
- MYGN 61.94
- Support Level
- HIFS $249.58
- MYGN $6.43
- Resistance Level
- HIFS $278.76
- MYGN $6.89
- Average True Range (ATR)
- HIFS 13.34
- MYGN 0.41
- MACD
- HIFS 0.40
- MYGN 0.15
- Stochastic Oscillator
- HIFS 95.50
- MYGN 91.18
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.